Skip to content

The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study

The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05811286
Enrollment
56
Registered
2023-04-13
Start date
2021-05-20
Completion date
2023-06-28
Last updated
2023-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Polyp Benign, Myoma;Uterus, Retained Products of Conception

Keywords

Endometrial polyp, Hysteroscopic surgery, Morcellation, Retained products of conception, Myoma

Brief summary

Polyps, intracavitary myomas and retained products of conception (RPOC) are common benign intracavitary lesions of the uterus and frequently cause abnormal uterine bleeding or pain. In general, intracavitary lesions are treated by operative hysteroscopy with bipolar resectoscopic removal under general anaesthesia, performed in the theatre (OR). Potential problems with this approach are thermal damage and impairment of visibility due to loose tissue fragments necessitating multiple entries for tissue removal. Recently, lesion morcellation by hysteroscopy has been introduced as an alternative technique. Compared to the resectoscopic approach, morcellation is reportedly associated with a shorter total procedure time, smaller fluid deficit and number of insertions. A few trials also registered a higher success rate in completeness of resection. No significant differences in odds of surgical complications have been reported. Most hysteroscopic morcellators have diameters up to 8 mm, for which cervical dilation under general anaesthesia is usually needed. Recently, companies have developed hysteroscopic morcellators with smaller diameters, e.g. 6.3 mm for the 19 Fr. intrauterine BIGATTI Shaver (IBS®). This means less need for cervical dilation, and potential use without anesthesia. At this moment, there are no prospective studies available on feasibility of the 19 Fr. intrauterine BIGATTI Shaver (IBS®). Before implementing hysteroscopic morcellation in our department, we need a feasibility study assessing the method in standard conditions in the operation room or in ambulatory setting under sedation. Trial objectives: Assessment of the feasibility of hysteroscopic morcellation of benign uterine intracavitary lesions. The primary objective is to assess the completeness of hysteroscopic resection in patients undergoing the procedure under general anesthesia or sedation. Secondary objectives are to assess perioperative parameters as operation time, need for cervical dilation, adverse events, pain, operator satisfaction; to assess quality of tissue for histological examination; to assess postoperative complications and pain.

Interventions

PROCEDUREHysteroscopic morcellation 19 Fr. intrauterine BIGATTI Shaver for uterine intracavitary lesions

With the shaver, the lesion is removed in the OR. We will include endometrial polyps, FIGO 0-1 myomas and retained products of conception. We will assess the completeness of hysteroscopic resection, operation time, need for cervical dilation, adverse events, pain, operator satisfaction; quality of tissue for histological examination, postoperative complications and pain.

Sponsors

Ziekenhuis Oost-Limburg
CollaboratorOTHER
Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients: * Female Ultrasonographic diagnosis of an intracavitary lesion, according the IETA terms and definitions * endometrial polyp * FIGO 0-1 myoma (maximum diameter 2 cm) * RPOC (maximum diameter 2 cm, no enhanced myometrial vascularity)

Exclusion criteria

* • Active vaginal bleeding * (possible) malignancy * \< 18y * Patient refusal * Pregnancy * Impossibility to access the uterine cavity (e.g. severe cervical stenosis) * Absence of intracavitary lesion (endometrial polyp, FIGO 0-1 myoma or RPOC) at hysteroscopy

Design outcomes

Primary

MeasureTime frameDescription
Completeness of resection of intracavitary lesions in 50 patients, when using a hysteroscopic Bigatti Shaver.During surgeryIf all tissue could be removed by the 19 Fr. intrauterine BIGATTI Shaver by direct visualisation at the end of the hysteroscopic procedure and at post-operative ultrasound evaluation.

Secondary

MeasureTime frameDescription
Need for cervical dilation during procedureDuring surgeryWas it necessary to perform any dilatation with
Volume of distension fluid used / loss (deficit) during procedureDuring surgeryDeficit in fluid used during surgery?
Operator satisfaction, assessed by verbal rating scaleAt the end of the procedureOperator satisfaction in terms of technique, ergonomics and general proceedings. The verbal rating scale includes Very negative; Negative; Intermediate; Positive; Very positive.
Operation timeDuring surgerytotal operation time and time necessary for the morcellation
Pain on the first postoperative day, assessed by verbal rating scaleDay 1 post-operativelyPain on the first day post-operatively. The verbal rating scale includes Very negative; Negative; Intermediate; Positive; Very positive.
Histology of the intracavitary lesion6 weeks post-operativelyIncidence of histological outcomes such as endometrial polyps, intracavitary myomas or remnant products of conception. This is a categorical variable.
Complications6 weeks after surgeryAdverse events during procedure/hospitalization and within the first 6 weeks after procedure

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026